Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05463796 · ClinicalTrials.gov registry record
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
A clinical trial of Lung Cancer and Barrett Esophagus, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 1
- Study location
NCT05463796: Recruiting study of Lung Cancer and Barrett Esophagus, sponsored by Dana-Farber Cancer Institute.
NCT05463796 is a study of Lung Cancer and Barrett Esophagus that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 5,000 participants, above the 924-participant average among 409 other Lung Cancer trials with a reported enrollment target (441% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05463796, a study of Lung Cancer and Barrett Esophagus, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.
Primary Outcome
The InAdvance Study will screen participants for precancerous conditions and cancer through blood tests and tissue biopsies. These biologic samples will be screened for precancerous conditions through routine clinical methods, as well as using novel research level technology. This could include germline testing, whole genome and whole exome sequencing. The participants will be followed serially to track their disease progression. Participants will fill out general health questionnaires, and we w
Conditions Studied
Interventions
- OTHER Samples
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2023-04-25 |
| Est. Completion | 2032-03-25 |
What NCT05463796 shows while recruiting
NCT05463796 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 924-participant average among 409 other Lung Cancer trials with a reported enrollment target (441% higher).
The record links to 10 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Samples is the first listed.
NCT05463796 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05463796 about?
NCT05463796 is a clinical study titled "InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer". This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The ...
What is the current status of trial NCT05463796?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2023-04-25. Estimated completion is 2032-03-25.
What conditions does trial NCT05463796 study?
This clinical trial studies the following conditions: Lung Cancer, Barrett Esophagus, Cancer Risk, Childhood Cancer Survivors, Cancer Predisposition Syndrome.
What interventions are being tested in trial NCT05463796?
The interventions under investigation include: Samples (OTHER).
Who is sponsoring clinical trial NCT05463796?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05463796 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05463796's enrollment target sits among peer trials
5,000 17th of 409 higher than 392 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI